137 related articles for article (PubMed ID: 36282671)
1. The role of soluble B cell maturation antigen as a biomarker in multiple myeloma.
Alomari M; Kunacheewa C; Manasanch EE
Leuk Lymphoma; 2023 Feb; 64(2):261-272. PubMed ID: 36282671
[TBL] [Abstract][Full Text] [Related]
2. Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma.
Wiedemann Á; Szita VR; Horváth R; Szederjesi A; Sebő A; Tóth AD; Masszi T; Varga G
Pathol Oncol Res; 2023; 29():1611171. PubMed ID: 37188125
[No Abstract] [Full Text] [Related]
3. Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
Bujarski S; Goldwater MS; Regidor BS; Jew S; Daniely D; Swift RA; Eades BM; Emamy-Sadr M; Souther E; Li M; Wang C; Xu N; Chen H; Spektor TM; Berenson JR
Eur J Haematol; 2021 Sep; 107(3):318-323. PubMed ID: 33993536
[TBL] [Abstract][Full Text] [Related]
4. Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma.
Meinl E; Krumbholz M
Curr Opin Immunol; 2021 Aug; 71():117-123. PubMed ID: 34330018
[TBL] [Abstract][Full Text] [Related]
5. Soluble B-cell maturation antigen in multiple myeloma.
Costa BA; Ortiz RJ; Lesokhin AM; Richter J
Am J Hematol; 2024 Apr; 99(4):727-738. PubMed ID: 38270277
[TBL] [Abstract][Full Text] [Related]
6. Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy.
Bujarski S; Udd K; Soof C; Chen H; Spektor TM; Safaie T; Li M; Stern J; Wang C; Xu N; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Regidor B; Sutanto C; Berenson JR
Target Oncol; 2021 Jul; 16(4):503-515. PubMed ID: 34097243
[TBL] [Abstract][Full Text] [Related]
7. [Expression of sBCMA in Newly Diagnosed Multiple Myeloma Patients and Its Relationship with Prognosis].
Zheng LL; Li B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1108-1112. PubMed ID: 37551484
[TBL] [Abstract][Full Text] [Related]
8. Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.
Thaler FS; Laurent SA; Huber M; Mulazzani M; Dreyling M; Ködel U; Kümpfel T; Straube A; Meinl E; von Baumgarten L
Neuro Oncol; 2017 Nov; 19(12):1618-1627. PubMed ID: 28521029
[TBL] [Abstract][Full Text] [Related]
9. Deciphering the Exact Sequence of Endogenous Soluble B Cell Maturation Antigen and Unbiased Quantitation in Multiple Myeloma Patient Samples by LC-MS.
Shen X; Dong X; Shi J; Chen H; Lan Y; Lim AC; Xie F; Ang A; Kratzer A; Rock DA; Rock BM
Clin Chem; 2024 Jan; 70(1):339-349. PubMed ID: 38175591
[TBL] [Abstract][Full Text] [Related]
10. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.
Ghermezi M; Li M; Vardanyan S; Harutyunyan NM; Gottlieb J; Berenson A; Spektor TM; Andreu-Vieyra C; Petraki S; Sanchez E; Udd K; Wang CS; Swift RA; Chen H; Berenson JR
Haematologica; 2017 Apr; 102(4):785-795. PubMed ID: 28034989
[TBL] [Abstract][Full Text] [Related]
11. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.
Pont MJ; Hill T; Cole GO; Abbott JJ; Kelliher J; Salter AI; Hudecek M; Comstock ML; Rajan A; Patel BKR; Voutsinas JM; Wu Q; Liu L; Cowan AJ; Wood BL; Green DJ; Riddell SR
Blood; 2019 Nov; 134(19):1585-1597. PubMed ID: 31558469
[TBL] [Abstract][Full Text] [Related]
12. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients.
Visram A; Soof C; Rajkumar SV; Kumar SK; Bujarski S; Spektor TM; Kyle RA; Berenson JR; Dispenzieri A
Blood Cancer J; 2021 Jun; 11(6):120. PubMed ID: 34168119
[TBL] [Abstract][Full Text] [Related]
13. Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment.
Jew S; Chang T; Bujarski S; Soof C; Chen H; Safaie T; Li M; Sanchez E; Wang C; Spektor TM; Emamy-Sadr M; Swift R; Rahbari A; Patil S; Souther E; Berenson JR
Br J Haematol; 2021 Jan; 192(2):272-280. PubMed ID: 32441777
[TBL] [Abstract][Full Text] [Related]
14. Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone.
Bujarski S; Sutanto C; Spektor TM; To J; Swift RA; Green T; Eades BR; Emamy-Sadr M; Souther E; Berenson JR
Hematol Oncol; 2022 Apr; 40(2):243-248. PubMed ID: 34982491
[TBL] [Abstract][Full Text] [Related]
15. Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.
Wang Y; Luong M; Guadiz C; Zhang M; Gorovits B
J Immunol Methods; 2019 Nov; 474():112642. PubMed ID: 31400410
[TBL] [Abstract][Full Text] [Related]
16. γ-Secretase directly sheds the survival receptor BCMA from plasma cells.
Laurent SA; Hoffmann FS; Kuhn PH; Cheng Q; Chu Y; Schmidt-Supprian M; Hauck SM; Schuh E; Krumbholz M; Rübsamen H; Wanngren J; Khademi M; Olsson T; Alexander T; Hiepe F; Pfister HW; Weber F; Jenne D; Wekerle H; Hohlfeld R; Lichtenthaler SF; Meinl E
Nat Commun; 2015 Jun; 6():7333. PubMed ID: 26065893
[TBL] [Abstract][Full Text] [Related]
17. The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma.
Sanchez E; Smith EJ; Yashar MA; Patil S; Li M; Porter AL; Tanenbaum EJ; Schlossberg RE; Soof CM; Hekmati T; Tang G; Wang CS; Chen H; Berenson JR
Target Oncol; 2018 Feb; 13(1):39-47. PubMed ID: 29230672
[TBL] [Abstract][Full Text] [Related]
18. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.
Chen H; Li M; Xu N; Ng N; Sanchez E; Soof CM; Patil S; Udd K; Bujarski S; Cao J; Hekmati T; Ghermezi M; Zhou M; Wang EY; Tanenbaum EJ; Zahab B; Schlossberg R; Yashar MA; Wang CS; Tang GY; Spektor TM; Berenson JR
Leuk Res; 2019 Jun; 81():62-66. PubMed ID: 31035033
[TBL] [Abstract][Full Text] [Related]
19. Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies.
Maglione PJ; Ko HM; Tokuyama M; Gyimesi G; Soof C; Li M; Sanchez E; Chen H; Radigan L; Berenson J; Cunningham-Rundles C
J Allergy Clin Immunol Pract; 2020 Jan; 8(1):283-291.e1. PubMed ID: 31430592
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
Lee L; Bounds D; Paterson J; Herledan G; Sully K; Seestaller-Wehr LM; Fieles WE; Tunstead J; McCahon L; Germaschewski FM; Mayes PA; Craigen JL; Rodriguez-Justo M; Yong KL
Br J Haematol; 2016 Sep; 174(6):911-22. PubMed ID: 27313079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]